Publication:
Indefinite Azacitidine Treatment Until Progression May Provide Long-Term Disease Control in Elderly Patients with Acute Myelogenous Leukemia

Simple item page
dc.contributor.authorBOZKURT, SÜHEYLA
dc.contributor.authorsEser, Ali; Sezgin, Aslihan; Kara, Osman; Uyar Bozkurt, Suheyla
dc.date.accessioned2022-03-14T09:03:47Z
dc.date.available2022-03-14T09:03:47Z
dc.date.issued2018-09-21
dc.description.abstractThe prognosis of acute myelogenous leukemia (AML) is poor in elderly patients. The mean survival rates at second and fifth years for AML were 10% and 2%, respectively. Here our aim was to demonstrate that the survival rate can be prolonged by long-term azacitidine (AZA) treatment. Complete remission was achieved at the end of the fourth and sixth courses of AZA treatment in three elderly patients with AML with a high blast count. The first patient was followed without any treatment after getting complete remission with four courses of AZA, and at the end of 1 year follow-up, the patient died due to pneumonia. Complete remission was obtained in the second and third patients after four and six courses of AZA, respectively. Second patient is still being followed up in complete remission at the end of the 20th course of AZA. Recurrence occurred at the end of the 16th AZA course in the third patient and he died after 20 months of the treatment. In elderly patients with AML with a high blast count, the continuation of AZA treatment improves the overall survival rates.
dc.identifier.doi10.14235/bs.2018.1829
dc.identifier.issn2148-2373
dc.identifier.urihttps://hdl.handle.net/11424/242327
dc.identifier.wosWOS:000446222000017
dc.language.isoeng
dc.publisherAVES
dc.relation.ispartofBEZMIALEM SCIENCE
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectElderly
dc.subjectacute myelogenous leukemia
dc.subjectazacitidine
dc.subjectACUTE MYELOID-LEUKEMIA
dc.subjectRISK MYELODYSPLASTIC SYNDROME
dc.subjectOLDER
dc.subjectCANCER
dc.subjectAGE
dc.titleIndefinite Azacitidine Treatment Until Progression May Provide Long-Term Disease Control in Elderly Patients with Acute Myelogenous Leukemia
dc.typearticle
dspace.entity.typePublication
local.avesis.id1285f541-be0c-4928-a61a-1de97b953782
local.import.packageSS16
local.indexed.atWOS
local.indexed.atTRDIZIN
local.journal.numberofpages3
oaire.citation.endPage235
oaire.citation.issue3
oaire.citation.startPage233
oaire.citation.titleBEZMIALEM SCIENCE
oaire.citation.volume6
relation.isAuthorOfPublicationdd039cf9-dfb8-4af0-b879-0b88c3a852fa
relation.isAuthorOfPublication.latestForDiscoverydd039cf9-dfb8-4af0-b879-0b88c3a852fa

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Department of Hematology, Bezmialem Vakif University School of Medicine, Istanbul, Turkey et al. - 2018 - Indefinite Azacitidine Treatment Until Progression.pdf
Size:
162 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs